

October 26, 2010

## **Astellas to Merge the Production Subsidiaries in Japan**

Tokyo, October 26, 2010 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that it will merge its production subsidiaries in Japan, Astellas Tokai Co., Ltd. (“Astellas Tokai”; headquarters: Yaizu, Shizuoka; president: Shunichi Hirashima) and Astellas Toyama Co., Ltd. (“Astellas Toyama”; headquarters: Toyama; president: Kinji Nakajima) and Astellas Pharma Chemicals Co., Ltd. (“Astellas Pharma Chemicals”; headquarters: Takahagi, Ibaraki; president: Motoyoshi Katano) on April 1, 2011.

The outline of the merger is described below.

### 1. Objective

Astellas currently has a subsidiary in Japan in each function, formulation, biotechnology and chemical synthesis. (formulation: Astellas Tokai, biotechnology: Astellas Toyama, chemical synthesis: Astellas Pharma Chemicals)

This merger will enable Astellas to establish the system of efficient operation and decision-making by consolidating 6 plants owned by 3 production subsidiaries. Further, Astellas aims to enhance each function of supplies of investigational drug substance and investigational drugs in a reliable and timely manner, earlier establishment of manufacturing know-how for new products and stable supplies of products for the Astellas Group.

### 2. Outline of the merger

#### 2.1 Time schedule

Merger on April 1, 2011

## 2.2 Method of merger and outline of the new company

Astellas Toyama and Astellas Pharma Chemicals will merge into Astellas Tokai as the surviving company. The following is an outline of the new company that will be created as a result of the merger.

Name: to be decided  
Date of establishment: January 25, 1986  
Headquarters: 2-3-11, Nihonbashi-Honcho, Chuo-Ku, Tokyo, Japan  
Representative: Shunichi Hirashima  
Capital: ¥100 million  
Total assets: ¥87,100 million(as of March 31,2010)  
Number of employees: ca.1,720  
Main businesses: manufacturing, marketing, import and export of drugs, etc

## 3. Outline of merging companies (as of March 31, 2010)

Name	Capital (JPY)	Month/Year of establishment	Main businesses
Astellas Tokai Co., Ltd.	100 million	January, 1986	manufacturing, marketing, import and export of drugs, etc.
Astellas Toyama Co., Ltd.	350 million	October, 2003	manufacturing, marketing, import and export of drugs, etc.
Astellas Pharma Chemicals Co., Ltd.	100 million	April, 2006	manufacturing, marketing, import and export of drugs, etc.

## 4. Effects on business

The merger will have insignificant effects on the business of Astellas.

#####

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 <a href="http://www.astellas.com/en">http://www.astellas.com/en</a>